ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

This study tested a combination of a targeted drug (brentuximab vedotin) and chemotherapy in 48 adults with a rare, aggressive lymphoma called CD30-positive peripheral T-cell lymphoma. The goal was to see how well the treatment shrinks tumors and what side effects occur. Particip…

This study is for people with a rare type of blood cancer called peripheral T-cell lymphoma that hasn't been treated yet. It compares standard chemotherapy alone versus adding either duvelisib or CC-486 to the chemo. The goal is to see if these added drugs can improve the chance …

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study looks at whether giving vitamin D to cancer patients who are low in it can help them live longer without their disease getting worse. About 565 adults with certain lymphomas or leukemia will either get vitamin D or no extra vitamin D. The goal is to see if vitamin D re…

This early-stage study tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in people with T-cell lymphoma that has come back or not responded to prior therapy. About 20 adults will receive the drugs in 28-day cycles for up to 13 cycles. The go…

This early-phase study tests a new type of CAR T-cell therapy made from donor cells (WU-CART-007) for people with CD7-positive blood cancers, including acute myeloid leukemia and T-cell lymphoma that have not responded to standard treatments. The therapy is designed to target and…

This study was designed to see if adding tazemetostat to standard CHOP chemotherapy could improve outcomes for people with untreated peripheral T cell lymphoma. It was withdrawn before any participants enrolled, so no results are available. The goal was to increase the number of …